(S)-3-Fluoropyrrolidine hydrochloride | CAS:136725-53-6

We serve (S)-3-Fluoropyrrolidine hydrochloride CAS:136725-53-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
(S)-3-Fluoropyrrolidine hydrochloride

Chemical Name:(S)-3-Fluoropyrrolidine hydrochloride
CAS.NO:136725-53-6
Synonyms:(S)-3-Fluoropyrrolidine hydrochloride
(S)-(+)-3-Fluoropyrrolidine hydrochloride
(R)-(-)-3-Fluoropyrrolidine Hydrochloride
Molecular Formula:C4H9ClFN
Molecular Weight:125.57200
 
Physical and Chemical Properties:
Density:1.436
Melting point:183-187.6ºC
Index of Refraction:1.454
 
Specification:
Appearance:Off-white Solid
Purity(GC):≥98.0%
Chiral purity:≥98.0%
The largest impurity:≤0.1%
Moisture:≤1.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate in organic syntheses



Contact us for information like (S)-3-Fluoropyrrolidine hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(R)-(-)-3-Fluoropyrrolidine Hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(R)-(-)-3-Fluoropyrrolidine Hydrochloride Use and application,(R)-(-)-3-Fluoropyrrolidine Hydrochloride technical grade,usp/ep/jp grade.


Related News: Fears over the continuing spread of coronavirus have also fueled resentment and discrimination. Some have become outcasts in their own country, shunned by hotels, neighbors and — in some areas — placed under controversial quarantine measures.2-Cyano-4-fluorobenzoic acid manufacturer Fears over the continuing spread of coronavirus have also fueled resentment and discrimination. Some have become outcasts in their own country, shunned by hotels, neighbors and — in some areas — placed under controversial quarantine measures.7-Chlorohept-1-ene supplier Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.p-Bromofluorobenzene vendor Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.The risk to the general public remains low. And we continue to be confident we are in a good position to respond to this developing situation.”